LifeWise
Health Plan of Washington

PHARMACY / MEDICAL POLICY – 5.01.614
Erythroid Maturation Agents

Effective Date:	June 1, 2024	RELATED MEDICAL POLICIES:
Last Revised:	May 24, 2024	None
Replaces:	N/A	

Select a hyperlink below to be directed to that section.

POLICY CRITERIA | DOCUMENTATION REQUIREMENTS | CODING
RELATED INFORMATION | EVIDENCE REVIEW | REFERENCES | HISTORY

∞ Clicking this icon returns you to the hyperlinks menu above.

Introduction

Beta thalassemia is an inherited blood disorder. Due to a change in one or more genes, the body doesn't make enough hemoglobin. Hemoglobin is a protein in red blood cells that carries oxygen to the body. When the body does not make enough hemoglobin or red blood cells, it causes a condition called anemia. Anemia leads to fatigue and weakness and can be mild, moderate, or severe. Treatment of anemia from beta thalassemia is meant to increase the number of healthy red blood cells. This policy describes when drugs called erythroid maturation agents used to treat anemia may be considered medically necessary.

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

Policy Coverage Criteria

Drug	Medical Necessity
Reblozyl (luspatercept-aamt) SC	**Reblozyl (luspatercept-aamt) may be considered medically necessary for the treatment of anemia in adult individuals with beta thalassemia when the following criteria are met:** • Individual is 18 years of age or older **AND** • Individual has beta thalassemia **AND** • Individual has received a minimum of 6 red blood cell (RBC) units in the past 6 months **AND** • Individual has no transfusion-free period >30 days during the past 6 months **AND** • Reblozyl is not being used as a substitute for RBC transfusions in individuals who require immediate correction of anemia **AND** • Reblozyl is prescribed by or in consultation with a hematologist **Reblozyl (luspatercept-aamt) may be considered medically necessary for the treatment of anemia in adult individuals failing an erythropoiesis stimulating agent (ESA) when the following criteria are met:** • Individual is 18 years of age or older **AND** • Individual has tried and failed or had intolerance to one ESA (e.g., epoetin alfa, darbepoetin) **AND** • Individual has very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPNRS-T). **AND** • Individual has received a minimum of 2 red blood cell (RBC) units in the past 8 weeks **AND** • Reblozyl is prescribed by or in consultation with a hematologist

Drug	Medical Necessity
	Reblozyl (luspatercept-aamt) may be considered medically necessary for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult individuals when the following criteria are met: • Individual is 18 years of age or older **AND** • Individual has very low- to intermediate-risk myelodysplastic syndromes (MDS) **AND** • Individual has received a minimum of 2 red blood cell (RBC) units in the past 8 weeks **AND** • Reblozyl is prescribed by or in consultation with a hematologist

Drug	Investigational
Reblozyl (luspatercept-aamt)	**All other uses of Reblozyl (luspatercept-aamt) for conditions not outlined in this policy are considered investigational.**

Length of Approval	
Approval	**Criteria**
Initial authorization	**Reblozyl (luspatercept-aamt) may be approved up to 6 months.**
Re-authorization criteria	**Future re-authorization of Reblozyl (luspatercept-aamt) may be approved up to 1 year as long as the drug-specific coverage criteria are met and chart notes demonstrate at the time of re-authorization a reduction in RBC transfusion burden from baseline.**

Documentation Requirements
The individual's medical records submitted for review for all conditions should document that medical necessity criteria are met. The record should include the following: • Office visit notes that contain the diagnosis, relevant history, physical evaluation, and RBC transfusion history

Coding

Code	Description
HCPCS	
J0896	Injection, luspatercept-aamt, 0.25 mg (Reblozyl)

Note: CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Related Information

Consideration of Age

The ages stated in this policy for which Reblozyl (luspatercept-aamt) is considered medically necessary are based on the ages approved in the FDA labeling.

Benefit Application

This policy is managed through the medical benefit.

Evidence Review

Background

β-thalassemia is a hereditary red blood cell disorder caused by mutations in the β-globin gene that can cause anemia and associated comorbidities such as bone deformities, ulcers, splenomegaly and treatment related sequelae such as iron overload. β-thalassemia is more common in Mediterranean countries, Central Asia and Southeast Asia. β-thalassemia can result in a range of phenotypes that include asymptomatic individuals to individuals with severe anemia. The cause of β-thalassemia is from a gene mutation which impacts the hemoglobin subunits and can be classified into categories such as β-thalassemia minor, β-thalassemia

intermedia and β-thalassemia major. Blood transfusion is the current standard of care for adult individuals with β-thalassemia who require RBC transfusion. With blood transfusion therapy supportive care in the form of iron chelation agents may be prescribed.

The burden of β-thalassemia in the U.S. is approximately 1 in 100,000 and varies by region based on immigration patterns. The economic impact of β-thalassemia can be profound over time as individuals with β-thalassemia major may be dependent on life-long blood transfusion regimens. The quality of life of subjects with β-thalassemia may diminish as treatment management modalities often require monitoring of symptoms, blood counts and iron levels but more importantly can be impacted by the negative side effects of blood transfusions such as iron overload and infusion related reactions.

β-thalassemia's are genetic disorders of hemoglobin synthesis characterized by deficient (β^{+}) or absent (β^{0}) synthesis of the β-globin subunit of hemoglobin that can result in anemia. The majority of individuals inherit their disorder as a mendelian recessive trait which can impart varying levels of phenotypic expression and disease conditions. Heterozygous individuals may be asymptomatic or exhibit light symptoms such as with mild anemia being labeled as β-thalassemia minor and homozygous individuals have more severe anemia of varying degrees and are labeled as β-thalassemia major or intermedia.

Luspatercept is a recombinant fusion protein comprised of the modified extracellular domain of the human activin receptor type IIB linked to the fragment crystallizable region (Fc) domain of human immunoglobin G1 which binds several endogenous TGF-β-superfamily ligands that diminishes Smad2/3 signaling. In mice models, luspatercept promoted erythroid maturation through differentiation of late-stage erythroid precursors (normoblasts). These models revealed that luspatercept decreased abnormally elevated Smad2/3 signaling and improved hematology parameters associated with ineffective erythropoiesis. Luspatercept activity in binding to and inhibiting Smad 2/3 ligands GDF11 and activin corrected anemia and ineffective erythropoiesis. In individuals with low RBC transfusion burden hemoglobin levels increased in 7 days of initiating treatment and correlated with the increase in luspatercept C_{MAX} and the greatest increase in hemoglobin was seen after the first dose.

Summary of Evidence

Efficacy

Luspatercept had consistent efficacy in decreasing transfusion burden compared to those receiving placebo as reported in the randomized, double-blind, placebo-controlled, Phase III

BELIEVE Trial. Individuals being managed for transfusion dependent β-thalassemia requiring 3 units of blood every 3 weeks for life adds a significant burden to treatment management. Luspatercept achieved reduction in transfusion burden across any 12- or 24-week period in the BELIEVE Trial demonstrating wide efficacy. 48/224 (21.4%) achieved the primary end point of a ≥33% reduction in RBC transfusion burden with a reduction of ≥2 RBC units from baselines during weeks 13-24 vs 5/112 (4.5%) of individuals in placebo. 158/224 (70.5%) of subjects achieved a greater than 33% reduction in RBC transfusion requirements during any consecutive 12 weeks of treatments vs 33/112 (29.5%) of placebo treated subjects. There were statistically significant findings that favored luspatercept for other secondary endpoints including:

- ≥33% reduction in transfusion burden at weeks 37-48: 19.6% (n=44 of 224 luspatercept-treated individuals) vs. 3.6% (n=4 of 112 placebo-treated individuals; p<0.001)
- ≥50% reduction in transfusion burden at weeks 13-24: 7.6% (n=17/224) vs. 1.8% (n=2/112; p=0.03)
- ≥50% reduction in transfusion burden at weeks 37-48: 10.3% (n=24/224) vs. 0.9% (n=1/112; p=0.002)

The expanded approval is based on interim results from the Phase 3 COMMANDS trial, which compared luspatercept with another ESA, epoetin alfa. Luspatercept demonstrated superior efficacy of concurrent RBC transfusion independence (RBC-TI) and hemoglobin (Hb) increase compared with epoetin alfa, regardless of ring sideroblast status. The trial randomized patients with very low-, low- or intermediate-risk MDS who were RBC transfusion independent and ESA-naïve to receive either subcutaneous luspatercept once every 3 weeks or epoetin alfa weekly. Of the patients who received luspatercept, 58.5% (n=86) achieved the primary endpoint of RBC-TI of at least 12 weeks with a mean Hb increase of at least 1.5 g/dL within the first 24 weeks, compared with 31.2% (n=48) of patients treated with epoetin alfa.

Safety

The safety profile of luspatercept was generally tolerable as the most common adverse events were mild to moderate and manageable without dose modification, delay or discontinuation. Common adverse events included bone pain, headache, and injection site reactions. Safety analyses by demographic subgroups did not reveal any significant differences from overall safety findings. The most common serious adverse events from clinical trials included anemia, DVT, fever, infection and septic shock. These side effects are commonly associated with the side effects related to the use of hematologic factors and subcutaneous injection site related reactions. Relevant warnings and precautions associated with luspatercept include

thromboembolic events (TEE) which were reported in 8/223 (3.6%) of subjects and included DVT and stroke followed by hypertension in 61/571 (10.7%) of subjects. There is limited data regarding pediatric individuals and the use of luspatercept. A warning label for embryo-fetal toxicity is stated. Pregnant and lactating women were excluded from the clinical study populations and throughout clinical development. Animal reproductive data was collected which resulted in adverse developmental outcomes. Outcomes included increased embryo-fetal mortality, alterations to growth, and structural abnormalities which occurred at levels higher than the maximum recommended human dose of 1.25 mg/kg.

In the Phase 3 COMMANDS trial, the most common (>10%) all-grade adverse reactions were diarrhea, fatigue, hypertension, peripheral edema, nausea, and dyspnea.

2021 Update

Reviewed Reblozyl (luspatercept-aamt) prescribing information and conducted a literature search on the management of anemia for thalassemias and myelodysplastic syndromes. No new information was identified that would result in changes to policy statements.

2022 Update

Reviewed Reblozyl (luspatercept-aamt) prescribing information. The prescribing information was updated in July 2022 and included information to discontinue Reblozyl for individuals with extramedullary hematopoietic (EMH) masses causing serious complications along with a warning regarding the risk for the development of EMH in individuals with beta thalassemia. No new information was identified that would result in changes to policy statements.

2023 Update

Reviewed Reblozyl (luspatercept-aamt) prescribing information. The prescribing information was updated in August 2023 and included new indication for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult individuals with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions. No new information was identified that would result in changes to policy statements.

2024 Update

Reviewed Reblozyl (luspatercept-aamt) prescribing information. Removed coverage from the pharmacy benefit to align with current benefit coverage.

References

1. Platzbecker U, Germing U, Götze KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017;18(10):1338-1347. doi:10.1016/S1470-2045(17)30615-0
2. Wire B, Piga A, Sciences B. Acceleron Announces Publication of Luspatercept Phase 2 B-Thalassemia Study Results in Media: 2019.
3. Piga A, Perrotta S, Gamberini MR, et al. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with b-thalassemia. Blood. 2019;133(12):1279-1289. doi:10.1182/blood-2018-10-879247
4. Rebloyzl [Prescribing Information]. Summit, NJ: Celgene; Revised August 2023.
5. Markham A. Luspatercept: First Approval. Drugs. 2020;80(1):85-90. doi:10.1007/s40265-019-01251-5
6. Galanello R, Origa R. B-thalassemia. Orphanet J Rare Dis. 2010;5(1):1-15. doi:10.1186/1750-1172-5-11
7. Attie KM, Allison MJ, Mcclure T, et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol. 2014;89(7):766-770. doi:10.1002/ajh.23732
8. Porter J. Beyond transfusion therapy: New therapies in thalassemia including drugs, alternate donor transplant, and gene therapy. Hematology. 2018;2018(1):361-370. doi:10.1182/asheducation-2018.1.361
9. Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382(2):140-151. doi:10.1056/NEJMoa1908892
10. MDS Revised - International Prognostic Scoring System (IPSS-R) | Calculate by QxMD. **https://www.mds-foundation.org/ipss-r-calculator/.** Accessed May 1, 2024.
11. IPSS-R Calculator App | MDS Foundation. Available at: **https://www.mds-foundation.org/ipss-r/.** Accessed May 1, 2024.
12. B-Thalassemia - NORD (National Organization for Rare Disorders). **https://rarediseases.org/rare-diseases/thalassemia-major/.** Accessed May 1, 2024.
13. Vichinsky EP, Bhatia S, Bojanowski J, et al. Standards of Care Guidelines for Thalassemia. Stand care Guidel Thalass. 2012:1-27.
14. Nienhuis AW, Nathan DG. Pathophysiology and clinical manifestations of the β-thalassemias. Cold Spring Harb Perspect Med. 2012;2(12):1-13. doi:10.1101/cshperspect.a011726
15. Zynteglo | European Medicines Agency. **https://www.ema.europa.eu/en/medicines/human/EPAR/zynteglo.** Accessed May 1, 2024.
16. bluebird bio Announces Launch in Germany of ZYNTEGLO (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype - bluebird bio, Inc. **http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-launch-germany-zynteglotm-autologous-cd34.** Accessed May 1, 2024.

17. Li J, Lin Y, Li X, Zhang J. Economic evaluation of chelation regimens for β-Thalassemia Major: A systematic review. Mediterr J Hematol Infect Dis. 2019;11(1):1-15. doi:10.4084/MJHID.2019.036

18. Thompson AA, Walters MC, Kwiatkowski J, et al. Gene therapy in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2018;378(16):1479-1493. doi:10.1056/NEJMoa1705342

19. Sekeres A, Larson R, Rosmarin A. Treatment of lower-risk myelodysplastic syndromes (MDS). UpToDate 2022. **https://www.uptodate.com/contents/treatment-of-lower-risk-myelodysplastic-syndromes-mds**. Accessed May 1, 2024.

20. Benz, Jr. E, Angelucci, E, Vichinsky, E, Tirnauer J. Management of thalassemia. UpToDate 2022. **https://www.uptodate.com/contents/management-of-thalassemia**. Accessed May 1, 2024.

History

Date	Comments
04/01/20	New policy, approved March 10, 2020, effective for dates of service on or after July 2, 2020, following 90-day provider notification. Add to Prescription Drug section. Reblozyl (luspatercept-aamt) may be considered medically necessary for the treatment of anemia in adult patients with beta thalassemia when criteria are met. Coverage criteria for Reblozyl (luspatercept-aamt) (HCPCS code J3590) becomes effective for dates of service on or after July 2, 2020.
07/01/20	Coding update. Added code J0896. Removed code J3590.
11/01/20	Interim Review, approved October 13, 2020. Added a new indication to Reblozyl (luspatercept-aamt) for the treatment of anemia in adults with MDS-RS or with MDS/MPN-RS-T who failed an ESA.
12/01/21	Annual Review, approved November 18, 2021. No changes to policy statements.
01/01/23	Annual Review, approved December 23, 2022. No changes to policy statements. Changed the wording from "patient" to "individual" throughout the policy for standardization.
11/01/23	Annual Review, approved October 10, 2023. Added a new indication to Reblozyl (luspatercept-aamt) for the treatment of anemia in ESA-naïve adults with very low- to intermediate-risk MDS.
06/01/24	Annual Review, approved May 24, 2024. No changes to policy statement. Removed coverage from the pharmacy benefit to align with current benefit coverage.

Scope: Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.

LifeWise

Discrimination is Against the Law

LifeWise Health Plan of Washington (LifeWise) complies with applicable Federal and Washington state civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. LifeWise does not exclude people or treat them differently because of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. LifeWise provides free aids and services to people with disabilities to communicate effectively with us, such as qualified sign language interpreters and written information in other formats (large print, audio, accessible electronic formats, other formats). LifeWise provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, contact the Civil Rights Coordinator. If you believe that LifeWise has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation, you can file a grievance with: Civil Rights Coordinator ─ Complaints and Appeals, PO Box 91102, Seattle, WA 98111, Toll free: 855-332-6396, Fax: 425-918-5592, TTY: 711, Email AppealsDepartmentInquiries@LifeWiseHealth.com. You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Ave SW, Room 509F, HHH Building, Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD). Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html. You can also file a civil rights complaint with the Washington State Office of the Insurance Commissioner, electronically through the Office of the Insurance Commissioner Complaint Portal available at https://www.insurance.wa.gov/file-complaint-or-check-your-complaint-status, or by phone at 800-562-6900, 360-586-0241 (TDD). Complaint forms are available at https://fortress.wa.gov/oic/onlineservices/cc/pub/complaintinformation.aspx.

Language Assistance

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 800-817-3056 (TTY: 711).

注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 800-817-3056（TTY：711）。

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 800-817-3056 (TTY: 711).

주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 800-817-3056 (TTY: 711) 번으로 전화해 주십시오.

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 800-817-3056 (телетайп: 711).

PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 800-817-3056 (TTY: 711).

УВАГА! Якщо ви розмовляєте українською мовою, ви можете звернутися до безкоштовної служби мовної підтримки.
Телефонуйте за номером 800-817-3056 (телетайп: 711).

ប្រយ័ត្ន៖ បើសិនជាអ្នកនិយាយ ភាសាខ្មែរ, សេវាជំនួយផ្នែកភាសា ដោយមិនគិតឈ្នួល គឺអាចមានសំរាប់បំរើអ្នក។ ចូរ ទូរស័ព្ទ 800-817-3056 (TTY: 711)។

注意事項：日本語を話される場合、無料の言語支援をご利用いただけます。800-817-3056（TTY:711）まで、お電話にてご連絡ください。

ማስታወሻ: የሚናገሩት ቋንቋ አማርኛ ከሆነ የትርጉም እርዳታ ድርጅቶች፣ በነጻ ሊያግዝዎት ተዘጋጀተዋል፡ ወደ ሚከተለው ቁጥር ይደውሉ 800-817-3056 (መስማት ለተሳናቸው: 711).

XIYYEEFFANNAA: Afaan dubbattu Oroomiffa, tajaajila gargaarsa afaanii, kanfaltiidhaan ala, ni argama. Bilbilaa 800-817-3056 (TTY: 711).

ملحوظة: إذا كنت تتحدث اذكر اللغة، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 800-817-3056 (رقم هاتف الصم والبكم: 711).

ਧਿਆਨ ਦਿਓ: ਜੇ ਤੁਸੀਂ ਪੰਜਾਬੀ ਬੋਲਦੇ ਹੋ, ਤਾਂ ਭਾਸ਼ਾ ਵਿੱਚ ਸਹਾਇਤਾ ਸੇਵਾ ਤੁਹਾਡੇ ਲਈ ਮੁਫਤ ਉਪਲਬਧ ਹੈ। 800-817-3056 (TTY: 711) 'ਤੇ ਕਾਲ ਕਰੋ।

ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 800-817-3056 (TTY: 711).

ໂປດຊາບ: ຖ້າວ່າ ທ່ານເວົ້າພາສາ ລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາ, ໂດຍບໍ່ເສັງຄ່າ, ແມ່ນມີພ້ອມໃຫ້ທ່ານ. ໂທຣ 800-817-3056 (TTY: 711).

ATANSYON: Si w pale Kreyòl Ayisyen, gen sèvis èd pou lang ki disponib gratis pou ou. Rele 800-817-3056 (TTY: 711).

ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 800-817-3056 (ATS : 711).

UWAGA: Jeżeli mówisz po polsku, możesz skorzystać z bezpłatnej pomocy językowej. Zadzwoń pod numer 800-817-3056 (TTY: 711).

ATENÇÃO: Se fala português, encontram-se disponíveis serviços linguísticos, grátis. Ligue para 800-817-3056 (TTY: 711).

ATTENZIONE: In caso la lingua parlata sia l'italiano, sono disponibili servizi di assistenza linguistica gratuiti. Chiamare il numero 800-817-3056 (TTY: 711).

توجه: اگر به زبان فارسی گفتگو می کنید، تسهیلات زبانی بصورت رایگان برای شما فراهم می باشد. با 800-817-3056 (TTY: 711) تماس بگیرید.